Dense breasts can make a mammogram harder to interpret and are also associated with a higher risk of breast cancer. They do not mean cancer is present. Whether an additional MRI, ultrasound or another test is worthwhile depends on your overall risk, the density category and the purpose of the examination. Buying every available scan is not a substitute for a coherent breast-screening plan.
If your executive health report mentions breast density, the useful next step is to understand what it changes for you. This guide separates the evidence for extra screening from the reasons it can also lead to unnecessary tests.
Does breast density mean I need an MRI?
Not automatically. Breast density describes the relative amount of fibroglandular tissue and fat seen on a mammogram. It is not something you can reliably judge by how your breasts look or feel. Reports commonly use four categories, ranging from almost entirely fatty to extremely dense. The two higher categories are described as dense. [1]
MRI is often considered for people at high risk, regardless of density. In other people, density is one factor in deciding whether extra imaging is appropriate. The American College of Radiology's density guidance, published in 2025, makes different recommendations for different combinations of risk and density. It does not recommend an identical extra scan for everyone. [1]
Need help putting a report in context? Ask The Wellness about a consultation. Bring the mammogram report, previous imaging and any family or genetic history so the appropriate breast specialist pathway can be discussed.
Why can a normal mammogram leave a question unanswered?
Dense tissue can mask some abnormalities on mammography. A normal result is reassuring within the limits of the examination, but it is not a guarantee that cancer is absent or will not develop before the next screen. Density also contributes to risk independently of its effect on image visibility. [1]
The decision about additional screening should therefore consider more than the words "normal mammogram". A clinician may assess your age, family history, previous breast biopsies, known genetic findings, previous chest radiotherapy and other risk factors. Not all of these have equal weight.
A risk estimate is a decision aid, not a prediction that you personally will or will not develop cancer. Ask which model was used and whether it is appropriate for your history.
What did the DENSE trial actually show?
The DENSE randomised trial studied 40,373 women aged 50 to 75 in the Netherlands who had extremely dense breasts and a normal screening mammogram. The rate of cancers diagnosed between screening rounds was 2.5 per 1,000 in the group invited for additional MRI, compared with 5.0 per 1,000 with mammography alone over two years. [2]
That is an absolute difference of 2.5 per 1,000, not a promise of a 50% reduction in your lifetime chance of dying from breast cancer. The trial's population and outcome matter. It does not prove that every younger woman with moderately dense tissue should have annual MRI.
There were trade-offs. Among women who underwent MRI, the first-round false-positive rate was 79.8 per 1,000 examinations. Additional tests and some biopsies therefore found no cancer. A thoughtful consultation explains both earlier detection and the possibility of a stressful investigation that ultimately proves benign. [2]
How do MRI, ultrasound and mammography differ?
Mammography and tomosynthesis: Mammography remains a central screening test. Tomosynthesis produces layered X-ray images and can improve detection, but it does not remove every limitation caused by dense tissue. [1]
Contrast-enhanced breast MRI: MRI can detect cancers that are not visible on a mammogram. It usually requires intravenous contrast for screening and can produce findings that need further imaging or biopsy. Suitability depends on clinical factors, including previous contrast reactions and relevant kidney or implant considerations. A dedicated breast MRI is not the same examination as a general whole-body MRI. [1]
Ultrasound: Ultrasound can answer targeted questions and may be considered as supplemental screening in selected circumstances. It can also increase false-positive findings. It is not automatically an equivalent substitute for MRI, nor should it be sold as a universal replacement for mammography. [1]
The best question is: "Which examination would change my care, and what would happen if it found something uncertain?"
What if I have a lump or other breast symptoms?
Symptoms require diagnostic assessment, not simply a screening upgrade. A new lump, new nipple inversion, unexplained nipple discharge, skin dimpling or another persistent change should be discussed promptly, even after a recent normal screen. A clinician may arrange a targeted diagnostic pathway with examination and appropriate imaging or sampling.
Do not wait for an annual executive assessment to mention a new symptom. Equally, breast pain or a change does not by itself mean cancer. The purpose of timely assessment is to find the cause.
How should breast screening fit into an executive programme?
A useful preventive programme should identify which breast assessment is appropriate, check what has already been done and explain who acts on the result. It should not treat the number of scans as a measure of quality.
The Wellness's executive programmes are published at £34,995, £14,995 and £6,995 as of 31 October 2026. Those are programme prices, not dedicated breast MRI quotes or a statement that supplemental breast imaging is included. Ask for an itemised plan and any additional specialist or imaging charges before booking.
For a busy diary, useful coordination means the correct test and follow-up route are agreed first. A convenient appointment has little value if it is the wrong examination or if an abnormal finding has no named clinical owner.
What should I bring to a breast-risk review?
- Your latest mammography report, including the density category if recorded.
- Earlier reports and access to images where available.
- A family history with relatives' ages at diagnosis, not only a list of cancer names.
- Previous biopsy results, breast operations and relevant genetic reports.
- A note of new symptoms and when they began.
- Questions about contrast, implants, pregnancy or breastfeeding where relevant.
Contact The Wellness to discuss the appropriate appointment. You can also email team@thewellnesslondon.com.
Common questions
Are dense breasts abnormal? Density is a common imaging characteristic. Its importance is how it affects risk assessment and the ability of mammography to detect abnormalities.
Can I choose ultrasound because I do not want contrast? Discuss that preference, but do not assume ultrasound provides the same information or detection performance as a recommended MRI.
Does a whole-body MRI replace mammography? No. Breast screening uses dedicated techniques and risk-based recommendations.
Should I repeat imaging immediately? Not solely because you have read the word "dense". Ask the responsible clinician what, if anything, should change in your plan.
Ask the team on WhatsApp, or call +44 20 3951 3429 to discuss the appropriate next step.
Evidence and further reading
- American College of Radiology. Supplemental Breast Cancer Screening Based on Breast Density: 2024 Update, published 2025. US appropriateness guidance, to be interpreted with your UK clinical team.
- Bakker and colleagues. Supplemental MRI Screening for Women with Extremely Dense Breast Tissue. New England Journal of Medicine, 2019. Randomised DENSE trial.
General information, not individual medical advice. Evidence and published programme prices checked 31 October 2026.